Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ASA404 + docetaxel
- Development stage
- Unknown
- Lead developer
- Novartis
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
ASA404 + docetaxel is a combination therapy consisting of ASA404 (vadimezan), a tumor-vascular disrupting agent (Tumor-VDA), and docetaxel, a taxane-based chemotherapy drug. ASA404 selectively causes the collapse of existing tumor blood supply leading to extensive tumor cell death, while docetaxel inhibits cell division by binding to microtubules. The combination was investigated for treatment of various solid tumors, particularly as second-line treatment for non-small cell lung cancer (NSCLC).
- Other names
- 5,6-Dimethylxanthenone-4-acetic acid + docetaxel
02
Targets
Microtubule
Beyond the preview
Go deeper on ASA404 + docetaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ASA404 + docetaxel.